Show simple item record

dc.contributor.authorHyer, SL
dc.contributor.authorPratt, B
dc.contributor.authorGray, M
dc.contributor.authorChittenden, S
dc.contributor.authorDu, Y
dc.contributor.authorHarmer, CL
dc.contributor.authorFlux, GD
dc.date.accessioned2018-04-27T08:39:31Z
dc.date.issued2018-06
dc.identifier.citationNuclear medicine communications, 2018, 39 (6), pp. 486 - 492
dc.identifier.issn0143-3636
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1654
dc.identifier.eissn1473-5628
dc.identifier.doi10.1097/mnm.0000000000000826
dc.description.abstractObjective The aim of this retrospective study was to assess the long-term outcome of a personalized dosimetry approach in Graves' disease aiming to render patients euthyroid from a planned thyroid absorbed dose of 60 Gy.Patients and methods A total of 284 patients with Graves' disease were followed prospectively following administration of radioiodine calculated to deliver an absorbed dose of 60 Gy. Patients with cardiac disease were excluded. Outcomes were analysed at yearly intervals for up to 10 years with a median follow-up of 37.5 months.Results A single radioiodine administration was sufficient to render a patient either euthyroid or hypothyroid in 175 (62%) patients, the remainder requiring further radioiodine. The median radioactivity required to deliver 60 Gy was 77 MBq. Less than 2% patients required 400-600 MBq, the standard activity administered in many centres. In the cohort receiving a single administration, 38, 32 and 26% were euthyroid on no specific thyroid medication at 3, 5 and 10 years, respectively. Larger thyroid volumes were associated with the need for further therapy. The presence of nodules on ultrasonography did not adversely affect treatment outcome.Conclusion A personalized dosimetric approach delayed the long-term onset of hypothyroidism in 26% of patients. This was achieved using much lower administered activities than currently recommended. Future studies will aim to identify those patients who would benefit most from this approach.
dc.formatPrint
dc.format.extent486 - 492
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectThyroid Gland
dc.subjectHumans
dc.subjectIodine Radioisotopes
dc.subjectOrgan Size
dc.subjectTreatment Outcome
dc.subjectRetrospective Studies
dc.subjectRadiometry
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectGraves Disease
dc.subjectMale
dc.subjectYoung Adult
dc.titleDosimetry-based treatment for Graves' disease.
dc.typeJournal Article
rioxxterms.versionofrecord10.1097/mnm.0000000000000826
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfNuclear medicine communications
pubs.issue6
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics/Radioisotope Physics (hon.)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics/Radioisotope Physics (hon.)
pubs.publication-statusPublished
pubs.volume39
pubs.embargo.termsNot known
icr.researchteamRadioisotope Physicsen_US
dc.contributor.icrauthorPratt, Brendaen
dc.contributor.icrauthorFlux, Glennen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0